Life Sciences

  • January 01, 2026

    4 High Court Cases To Watch This Spring

    The U.S. Supreme Court justices will return from the winter holidays to tackle several constitutional disputes that range from who is entitled to birthright citizenship to whether transgender individuals are entitled to heightened levels of protection from discrimination. 

  • January 01, 2026

    Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook

    In 2025, President Donald Trump put 20 district and six circuit judges on the federal bench. In the year ahead, a fight over home state senators' ability to block district court picks could make it more difficult for him to match that record.

  • January 01, 2026

    BigLaw Leaders Tackle Growth, AI, Remote Work In New Year

    Rapid business growth, cultural changes caused by remote work and generative AI are creating challenges and opportunities for law firm leaders going into the New Year. Here, seven top firm leaders share what’s running through their minds as they lie awake at night.

  • December 24, 2025

    Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B

    French pharmaceutical giant Sanofi SA said Wednesday that it will buy Dynavax Technologies, a U.S. vaccine developer, for $2.2 billion in a recommended cash deal to expand its adult immunization products.

  • December 23, 2025

    Top Illinois Decisions Of 2025

    State and federal courts have handed down rulings in Illinois cases this year that made clear plaintiffs must allege concrete injury for common law standing, narrowed the scope of the federal anti-kickback statute and laid out a new standard for certifying collective actions.

  • December 23, 2025

    3 Federal Circuit Clashes To Watch In January

    The Federal Circuit is set to hear several intellectual property cases in January, including one over a nine-figure patent judgment against cybersecurity company Gen Digital tied to a contempt finding against a major law firm that represented it, and another over the tech industry's long-running crusade against patent review denials based on related litigation.

  • December 23, 2025

    Philly Joins MDL Against Drug Cos., PBMs Over Insulin Prices

    Philadelphia on Tuesday sued drug manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with several pharmacy benefit managers, joining multidistrict litigation in New Jersey federal court accusing the companies of illegally inflating the price of insulin.

  • December 23, 2025

    Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'

    Amarin Pharma Inc. on Tuesday urged the U.S. Supreme Court to reject the U.S. solicitor general's call to hear a patent case involving generic drug "skinny labels," saying the dispute over the company's heart drug Vascepa deals with factual issues not suitable for high court review.

  • December 23, 2025

    AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit

    Medical device provider AdaptHealth Corp. has agreed to pay $35 million to settle a lawsuit accusing it of deceiving shareholders about its revenue projections as it "routinely engaged in improper and unethical tactics to inflate sales numbers." 

  • December 23, 2025

    Dem Sens. Blast Idea Of Charging Value-Based Patent Fees

    A group of Democratic U.S. senators has asked Commerce Secretary Howard Lutnick not to move forward with a proposed overhaul of the U.S. patent fee system that reportedly would implement fees based on a patent's value, saying such changes would create a "prohibitive bar to innovation for start-ups and other small-to-mid-size businesses."

  • December 23, 2025

    Squires Will Review If Hydrafacial's ITC Win Should End IPR

    U.S. Patent and Trademark Office Director John Squires has paused the Patent Trial and Appeal Board's review of a Hydrafacial LLC skin treatment patent to consider the effect of a related U.S. International Trade Commission decision.

  • December 23, 2025

    Federal Agencies Urge 9th Circ. To Lift Layoff Freeze

    The U.S. government urged the Ninth Circuit to stay a court order barring agencies from laying off workers through next month under the shutdown deal, saying the court intruded on federal labor panels' territory and the funding resolution didn't bar layoffs agencies had in the works.

  • December 23, 2025

    Blue Cross Seeks McDonald Hopkins' Fraud Warning Docs

    Advice that McDonald Hopkins LLC gave a Florida hospital manager about potential exposure to criminal prosecution for healthcare fraud is neither privileged nor work product, and so should be handed over to a Blue Cross health insurer being sued for malicious prosecution in Georgia federal court, the insurer said.

  • December 23, 2025

    Top New Jersey Cases Of 2025

    New Jersey courts saw some history-making litigation come to a close over the course of 2025, including the largest environmental settlement ever achieved by a single state and the first clergy abuse trial verdict since the statute of limitations on child sexual abuse claims was extended. Another notable development was the state's federal bench exercising a rarely used authority to reject President Donald Trump's pick for interim U.S. attorney.

  • December 23, 2025

    Sanofi Eczema Drug Linked To Lymphoma, Suit Says

    Drug manufacturers Regeneron Pharmaceuticals and Sanofi were hit with a lawsuit Monday from a Georgia woman alleging the companies have covered up a "strong and consistent causal relationship" between their drug Dupixent and a form of non-Hodgkins lymphoma.

  • December 23, 2025

    Baker Botts Hires 2 New DC Partners For Enviro, IP Team

    Baker Botts LLP has hired two new partners in its intellectual property and environmental safety and incident response groups, who will both be based in the firm's Washington, D.C., office, Baker Botts said in recent announcements.

  • December 23, 2025

    'Gas Station Heroin' Cos. Sued Over User's Overdose

    The estate of a woman who died of a tianeptine overdose is suing the makers and sellers of tianeptine products in Pennsylvania state court, saying while they market the products as safe diet supplements, they're actually highly addictive opioids.

  • December 23, 2025

    Johnson & Johnson Hit With $1.5B Talc Verdict In Baltimore

    A Baltimore jury late Monday returned a walloping verdict of more than $1.5 billion in favor of a woman who claimed that Johnson & Johnson talc products caused her mesothelioma, which her attorneys say is the largest verdict against the company for a single plaintiff.

  • December 22, 2025

    Becton Muscles Out Hernia Mesh Rivals, Antitrust Suit Says

    Tela Bio Inc. slapped Becton Dickinson and Co. and its subsidiaries with an antitrust lawsuit Friday in Pennsylvania federal court accusing the medical tech giant of abusing its dominant position in the hernia mesh market to block Tela's product and keep Becton's "costlier and clinically inferior" mesh on hospital shelves in the U.S.

  • December 22, 2025

    Top Gov't Contracts Cases Of 2025

    The Federal Circuit and U.S. Court of Federal Claims ruled on several consequential issues impacting government contractors this year, including deciding who constitutes an "interested party" capable of lodging a bid protest and invalidating a settlement between the Pentagon and one of its major contractors. Here, Law360 reviews the top government contracts-related rulings in 2025.

  • December 22, 2025

    Apple Seeks To Overturn $634M Masimo Patent Verdict

    Apple has urged a California federal judge to grant its combined motion for judgment or a new trial for its $634 million trial loss over a Masimo patient monitor patent, arguing that no reasonable jury could have reached the verdict and that the tech giant was "severely prejudiced" by erroneous court rulings.

  • December 22, 2025

    6th Circ. Vacates Pharma Salesman's $6.8M Restitution Order

    The Sixth Circuit vacated a nearly $7 million restitution order against a pharmaceutical salesman convicted of healthcare fraud, finding an Ohio federal court erred in calculating that amount and apportioning liability.

  • December 22, 2025

    Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss

    MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic-drug maker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that the appeal "reveals no district court error, just Novartis' poor litigation strategy."

  • December 19, 2025

    Colo. IVF Co. Says AI Fertility Co. Owes Nearly $900K

    The maker of an in vitro fertilization incubator system has filed a breach of contract lawsuit in Colorado federal court, claiming an artificial intelligence-based fertility company owes it nearly $900,000 for embryoscope incubator systems it sold to the lab.

  • December 19, 2025

    AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims

    A Massachusetts federal judge spared AstraZeneca unit Alexion on Friday from half of a nonprofit insurer's proposed class action, finding the plaintiff too far removed from anticompetitive patent fraud that allegedly propped up blood disorder treatment Soliris, while preserving accusations that Alexion brought sham infringement allegations against would-be rivals.

Expert Analysis

  • What Patent Claim 'Invalidity' Means In Different Forums

    Author Photo

    A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler.

  • Rebuttal

    BigLaw Settlements Should Not Spur Ethics Deregulation

    Author Photo

    A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.

  • How Big Pharma Has Responded To FTC Delisting Demands

    Author Photo

    Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics.

  • 5 Ways Lawyers Can Earn Back The Public's Trust

    Author Photo

    Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.

  • USPTO's AI Tool Redefines Design Patent Landscape

    Author Photo

    The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.

  • Class Actions At The Circuit Courts: August Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses key takeaways from federal appellate decisions involving topics including antitrust, immigration, consumer fraud, birthright citizenship under the Fourteenth Amendment, and product defects.

  • Series

    Hiking Makes Me A Better Lawyer

    Author Photo

    On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.

  • What US-India Trade Deal Will Mean For Indian Pharma

    Author Photo

    Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.

  • Opinion

    Time For Full Disclosure Of Third-Party Funding In MDLs

    Author Photo

    It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow.

  • Series

    Law School's Missed Lessons: Negotiation Skills

    Author Photo

    I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.

  • Conflicting Developments In Homelessness Legal Landscape

    Author Photo

    Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

  • Location Data And Online Tracking Trends To Watch

    Author Photo

    Regulators and class action plaintiffs are increasingly targeting companies' use of online tracking technologies and geolocation data in both privacy enforcement and litigation, so organizations should view compliance as a dynamic, cross-functional responsibility as scrutiny becomes increasingly aggressive and multifaceted, say attorneys at Arnold & Porter.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.